CFO: Frontier Medicines.
Covalent small fragment chemistry, chemoproteomics and machine learning in Oncology and Immunology.
Classical violinist.
Investment banker: >$100bn in M&A, >$12bn in equity.
Physics student.
Adam Davidson, CEO of Trident Royalties plc (#TRR), discusses the major breakthrough at Thacker Pass for Lithium Americas Corp. (NYSE: LAC), of which #TRR holds a net 1.05% gross revenue royalty over https://lnkd.in/dtanU-F8
LAC has received a conditional commitment from the U.S. Department of Energy for a $2.26 billion loan to proceed with the Thacker Pass Lithium Project in Nevada.
The loan, combined with a second tranche of funding from General Motors worth US$330m, effectively finances the Project through to Phase 1 production in 2027.
Trident holds a net 1.05% gross revenue royalty over Thacker Pass (after expected exercise of a partial royalty buyback), which would see $13.2 million to Trident.
Adam Davidson, CEO of Trident Royalties, explains the significance of the news for their investors, highlighting that analysts expect the income from Thacker Pass to become the largest revenue stream in the Company’s entire portfolio, comprising between a 30% and 40% of total Net Asset Value.
In this interview with focusIR, investors will also learn:
• What level of involvement Trident is likely to have with Thacker Pass during the coming years
• How well the company is placed to handle volatility in the lithium market
• Where Davidson sees the biggest opportunities to pick up new assets, specifically with regard to uranium
• How he rates the company’s current performance
• How likely it is that Trident will be adding assets in the second quarter
Davidson concludes by highlighting how happy he is with the progress made by the company over the last year, saying that “if you look at where we were last year, Thacker Pass was still going through permitting challenges, the DoE loan obviously wasn’t there [etc]… fast forward to today, effectively our share count is roughly the same, Thacker Pass has been massively derisked, we’ve added four acquisitions, we’ve lowered our cost of debt with the recently announced revolving facility with BMO and CIBC, so everything has moved forward in the right direction - we couldn’t be happier with the portfolio.”
Adam Davidson, CEO of Trident Royalties, was interviewed by Tom Warner, financial reporter at focusIR.
Last week, Reorg and Kobre & Kim held a deep dive into InterCement and its expected exit from Brazil and Argentina, as well as the legal challenges, opportunities and potential outcomes for offshore creditors. Access the replay here: https://ow.ly/EnEu50R63V4
Imagine being set to close on your first bigger apartment deal (50+ units)…
And then one of your big investors pulls out last minute.
This is exactly what happened to Charles Carillo of Harborside Partners.
Charles goes into how him and his team responded and became victorious in closing this amazing life changing deal.
But not only that, he details exactly what he would have done differently to avoid this brain damage and many more actionable tips and tricks that he uses to scale Harborside’s portfolio without limits.
Tune in now! 👇👇👇
https://lnkd.in/e2_459gn
Trading competitions are the future of #Forex prop firms. What better way to find the cream of the crop than making people FIGHT for it? The real talent who may be just too poor at this moment, finally get their shot. Making money for themselves and more importantly, the prop firm.
SmallCap 60: KIDOZ Inc. (KIDZ: TSXV) Has A Great Group of Staff That's Executing on all 3 Pillars
1️⃣ Technology
2️⃣ Operations
3️⃣ Sales Commercial
How do they do it?
✔️ Delivering great media, with great value, with great service on a great platform = more spending 💰
#smallcaps#smallcapstocks#pennystocks#smallcap#adtech
In a world where dividends symbolize shareholder return, SilverBow Resources stands out by not offering one, unlike its peers. Kimmeridge Energy proposes introducing dividends, suggesting a potential uplift in company value. Is this the missing puzzle piece for SilverBow, or is it a strategy fraught with risks?
https://lnkd.in/gB7Mt6ij | #sharholders#silverbow#dividends#companyvalue
CFO: Frontier Medicines. Covalent small fragment chemistry, chemoproteomics and machine learning in Oncology and Immunology. Classical violinist. Investment banker: >$100bn in M&A, >$12bn in equity. Physics student.
1moCongrats, Drew Valentine !!